Author

Takeyoshi Alfonso Kondo

Institution: Exelixis (United States)

Observed institution: Exelixis (United States)

OpenAlex ID: A5000235892

Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).

2017 · Sumanta K. Pal, Robert J. Motzer, et al. · Journal of Clinical Oncology · 1

Works count: 1

Citation count: 1

H-index: 1

I10-index: